HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats | Zendy

Hitomi Usui | Zendy; Kenichi Shikata | Zendy; Mitsuhiro Matsuda | Zendy; Shinichi Okada | Zendy; Daisuke Ogawa | Zendy; Tetsuji Yamashita | Zendy; Kazuyuki Hida | Zendy; Minoru Satoh | Zendy; Jun Wada | Zendy; Hirofumi Makino | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats

Author(s) -

Hitomi Usui,

Kenichi Shikata,

Mitsuhiro Matsuda,

Shinichi Okada,

Daisuke Ogawa,

Tetsuji Yamashita,

Kazuyuki Hida,

Minoru Satoh,

Jun Wada,

Hirofumi Makino

Publication year - 2003

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/18.2.265

Subject(s) - medicine , hmg coa reductase , diabetic nephropathy , nephropathy , reductase , pharmacology , diabetes mellitus , endocrinology , hydroxymethylglutaryl coa reductase , enzyme , biochemistry , chemistry

An inflammatory process may be one of the critical factors that contribute to the development of diabetic nephropathy (DN). We reported previously that intercellular adhesion molecule-1 (ICAM-1) is up-regulated and promotes macrophage infiltration in the glomeruli of diabetic rats. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have recently been emphasized to have anti-inflammatory effects; inhibition of leukocyte adhesion and migration, independent of the cholesterol-lowering effect. The present study was designed to test the hypothesis that statins prevent the development of DN by pleiotropic effects.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research